Evaluation of a hospital-wide vancomycin-dosing nomogram in patients with continuous-flow left ventricular assist devices.

The International Journal of Artificial Organs
Sylvie F HallBrad Williams

Abstract

Hemodynamic derangements due to heart failure are associated with alterations in pharmacokinetics. Although use of mechanical circulatory support mitigates such derangements, little evidence is available regarding pharmacokinetics in patients with LVADs. A previous pharmacokinetic analysis of vancomycin among patients with LVADs observed a reduced volume of distribution and clearance compared with estimates based on population kinetics. A total of 28 adult patients with LVADs hospitalized between January 2014 and May 2018 who received vancomycin through a pharmacist dosing consult were included. Internal medicine patients without heart failure receiving vancomycin were enrolled in a 2:1 fashion to make a control group. Exclusion criteria were unstable renal function, ESRD, acute decompensation, cardiac surgery within the preceding 5 days, or weight >110 kg. No difference was observed in the proportion achieving goal trough (64% of LVAD patients vs 71% control patients, p = 0.50). However, mean trough was significantly higher among LVAD patients (23.4 mg/L vs 17.7 mg/L, p = 0.017). Furthermore, there was a significant difference in the distribution of trough levels (p = 0.025) with LVAD patients being more likely to attain level...Continue Reading

References

Nov 1, 1976·Clinical Pharmacokinetics·N L Benowitz, W Meister
Aug 1, 1988·Clinical Pharmacokinetics·F V Shammas, K Dickstein
Jan 1, 1985·European Journal of Clinical Pharmacology·M A NaafsJ Silberbusch
Mar 3, 2007·Critical Care : the Official Journal of the Critical Care Forum·Ravindra L MehtaUNKNOWN Acute Kidney Injury Network
Jul 14, 2012·European Journal of Clinical Pharmacology·Yuko ShimamotoKatsuya Komori
Oct 9, 2012·Current Opinion in Infectious Diseases·Brett Janson, Karin Thursky
Mar 13, 2014·The International Journal of Artificial Organs·Douglas L JenningsDavid E Lanfear
Sep 23, 2014·Journal of the American College of Cardiology·Jerry D EstepSherif F Nagueh
Jun 10, 2018·Journal of Clinical Pharmacy and Therapeutics·R K TunneyH J DeAntonio

❮ Previous
Next ❯

Software Mentioned

R Foundation for Statistical Computing
R

Related Concepts

Related Feeds

Artificial Heart & Ventricular Assist Devices

Total artificial hearts (TAH) and ventricular assist devices (VADs) provide cardiac support for patients with end-stage heart disease and have significantly improved the survival of these patients. Discover the latest research on Artificial Heart and Ventricular Assist Devices here.